Hanan Khadam-Makhoul, MD
Pulmonary Disease · Little Rock, ARNPI 1184838369
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,582 of the $15,492 with a category attached, or 81.2%. It is spread thinly across 37 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,924, more than ten times the $493 reported in 2019. Among pulmonary disease clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 624 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- GSK$3K
- AstraZeneca$3K
- Actelion Pharmaceuticals US, Inc.$900
- Sanofi$877
- Regeneron Healthcare Solutions, Inc.$871
- plus $5K from 31 others
What the payments were for
- Travel & lodging$1,1047%
- Food & beverage$12,58281%
- Education$1,80612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $3,007 |
| GSK | 160 | $2,760 |
| AstraZeneca | 120 | $2,506 |
| Actelion Pharmaceuticals US, Inc. | 39 | $900 |
| Sanofi | 44 | $877 |
| Regeneron Healthcare Solutions, Inc. | 41 | $871 |
| Insmed, Inc. | 26 | $575 |
| Boehringer Ingelheim | 29 | $545 |
| United Therapeutics Corporation | 14 | $455 |
| Amgen | 19 | $391 |
| Mallinckrodt Hospital Products Inc. | 15 | $380 |
| Mylan Specialty L.p. | 18 | $316 |
| Genentech USA, Inc. | 13 | $256 |
| Pulmonx Corporation | 3 | $214 |
| Grifols USA, LLC | 9 | $178 |
| Philips North America LLC | 8 | $151 |
| Baxter Healthcare | 7 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $130 |
| Verona Pharma, Inc. | 6 | $116 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Sunovion Pharmaceuticals Inc. | 5 | $87 |
| Viatris Specialty LLC | 4 | $85 |
| Vifor Pharma, Inc. | 3 | $63 |
| Advanced Respiratory, Inc | 3 | $53 |
| Electromed, Inc. | 4 | $51 |
| Merck | 2 | $39 |
| Inogen, Inc. | 3 | $38 |
| CSL Behring | 2 | $32 |
| Circassia Inc. | 2 | $27 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Medtronic | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Liquidia Technologies, Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,971
- ZEPHYR ENDOBRONCHIAL VALVE$167
- PULMONX CHARTIS TABLET CONSOLE$167
- CHARTIS CATHETER$167
- ZEPHYR DELIVERY CATHETER$167
- TYVASO$157
- NUCALA$122
- BREZTRI$111
- AREXVY$102
How this compares
$15,492 in reported general payments places this provider in the 90th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 12 | $1,076,725 |
| UptraviSelexipag | 22 | $521,232 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 633 | $441,670 |
| OfevNintedanib Esylate | 34 | $363,955 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 417 | $290,633 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 14 | $234,562 |
| Spiriva RespimatTiotropium Bromide | 212 | $130,706 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $105,161 |
| Breo ElliptaFluticasone/Vilanterol | 195 | $96,946 |
| Ambrisentan | 29 | $78,299 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 147 | $71,756 |
| Fasenra PenBenralizumab | 11 | $66,389 |
| SymbicortBudesonide/Formoterol Fumarate | 180 | $53,933 |
| Advair HfaFluticasone Propion/Salmeterol | 119 | $48,281 |
| OzempicSemaglutide | 45 | $42,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $380 | $1,076,72512 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,760 | $639,4611,099 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $545 | $577,113415 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $900 | $521,23222 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra | $2,506 | $389,954697 claims |
| CSL BehringHizentra | $32 | $105,16113 claims |
| Lilly USA, LLCMounjaro | $14 | $13,87213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Nikhil MeenaLittle Rock$63K
- Raghu ReddyLittle Rock$13K
- Eyad AbochaleLittle Rock$11K
- Krishna Siva Sai KakkeraLittle Rock$11K
- Samer HomsiLittle Rock$9K
- Nathan HillLittle Rock$9K
- Jose CaceresLittle Rock$6K
- Moeezullah BegLittle Rock$5K
- Rosa ArancibiaLittle Rock$4K
- Nancy RectorLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.